AETHLON MEDICAL INC — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Aethlon Medical (AEMD, $5.7M market cap) is combining with North Immunology via business combination where North becomes a wholly owned subsidiary of AEMD. Concurrent private placement of $180M (inclusive of $34M convertible note) will be raised. Post-closing capitalization: AEMD 4.75%, North 43.17%, PIPE investors 52.08% (71.2M total shares). North's lead asset NOR-101 is a half-life extended anti-IL-13 × IL-18 bispecific antibody targeting atopic dermatitis, with Phase 1a planned Q1 2027.
Why this rating
Transformational M&A for $5.7M company: massive capital infusion ($180M), new clinical-stage biotech platform, and 43% post-deal ownership. Existential recapitalization.
Tradability signal
NO TRADE
No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.46% over 4 hrs, n=30). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $5.01 ▲ 0.00% | at our read · unknown $5.01 | +10 min · unknown $5.01 ▲ 0.00% | +30 min · unknown $5.05 ▲ 0.80% | +1 hr · unknown $5.02 ▲ 0.28% | +4 hrs · unknown $5.00 ▼ 0.30% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.